{"id":"https://openalex.org/W2981310191","doi":"https://doi.org/10.1182/blood.v112.11.328.328","title":"Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial","display_name":"Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial","publication_year":2008,"publication_date":"2008-11-16","ids":{"openalex":"https://openalex.org/W2981310191","doi":"https://doi.org/10.1182/blood.v112.11.328.328","mag":"2981310191"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v112.11.328.328","doi":"https://doi.org/10.1182/blood.v112.11.328.328","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.328.328","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5049924304","display_name":"Anders \u00d6sterborg","orcid":"https://orcid.org/0000-0001-6489-4865","observed_orcids":["https://orcid.org/0000-0001-6489-4865"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Anders Osterborg","raw_affiliation_strings":["Deptartment of Hematology, Karolinska Hospital, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Deptartment of Hematology, Karolinska Hospital, Stockholm, Sweden","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":["Moores UCSD Cancer Center, Univ. of California, San Diego, La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moores UCSD Cancer Center, Univ. of California, San Diego, La Jolla, CA, USA","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054654885","display_name":"Ji\u0159\u0131\u0301 Mayer","orcid":"https://orcid.org/0000-0003-0567-9887","observed_orcids":["https://orcid.org/0000-0003-0567-9887"]},"institutions":[{"id":"https://openalex.org/I4210102302","display_name":"University Hospital Brno","ror":"https://ror.org/00qq1fp34","country_code":"CZ","type":"healthcare","lineage":["https://openalex.org/I4210102302"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Jiri Mayer","raw_affiliation_strings":["Hematology/Oncology, University Hospital Brno, Brno, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, University Hospital Brno, Brno, Czech Republic","institution_ids":["https://openalex.org/I4210102302"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019866348","display_name":"Stephan Stilgenbauer","orcid":"https://orcid.org/0000-0002-6830-9296","observed_orcids":["https://orcid.org/0000-0002-6830-9296"]},"institutions":[{"id":"https://openalex.org/I196349391","display_name":"Universit\u00e4t Ulm","ror":"https://ror.org/032000t02","country_code":"DE","type":"education","lineage":["https://openalex.org/I196349391"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Stephan Stilgenbauer","raw_affiliation_strings":["Internal Medicine III, University of Ulm, Ulm, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Internal Medicine III, University of Ulm, Ulm, Germany","institution_ids":["https://openalex.org/I196349391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108225018","display_name":"Catherine D. Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334287468","display_name":"Nottingham University Hospitals NHS Trust","ror":"https://ror.org/05y3qh794","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1334287468"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Catherine D Williams","raw_affiliation_strings":["Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre for Clinical Haematology, Nottingham University Hospitals, Nottingham, United Kingdom","institution_ids":["https://openalex.org/I1334287468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065480326","display_name":"Andrzej Hellmen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I75124487","display_name":"Gda\u0144sk Medical University","ror":"https://ror.org/019sbgd69","country_code":"PL","type":"education","lineage":["https://openalex.org/I75124487"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Andrzej Hellmen","raw_affiliation_strings":["Department of Hematology, Medical University of Gdansk, Gdansk, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Medical University of Gdansk, Gdansk, Poland","institution_ids":["https://openalex.org/I75124487"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087571749","display_name":"Tadeusz Robak","orcid":"https://orcid.org/0000-0002-3411-6357","observed_orcids":["https://orcid.org/0000-0002-3411-6357"]},"institutions":[{"id":"https://openalex.org/I4210122071","display_name":"Medical University of Lodz","ror":"https://ror.org/02t4ekc95","country_code":"PL","type":"education","lineage":["https://openalex.org/I4210122071"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Tadeusz Robak","raw_affiliation_strings":["Department of Hematology, Medical University of Lodz, Lodz, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Medical University of Lodz, Lodz, Poland","institution_ids":["https://openalex.org/I4210122071"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013974745","display_name":"Richard R. Furman","orcid":"https://orcid.org/0000-0003-1677-7626","observed_orcids":["https://orcid.org/0000-0003-1677-7626"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard R Furman","raw_affiliation_strings":["Department of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047631289","display_name":"Peter Hillmen","orcid":"https://orcid.org/0000-0001-5617-4403","observed_orcids":["https://orcid.org/0000-0001-5617-4403"]},"institutions":[{"id":"https://openalex.org/I2801331674","display_name":"St James's University Hospital","ror":"https://ror.org/013s89d74","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799390153","https://openalex.org/I2801331674"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter Hillmen","raw_affiliation_strings":["Department of Haematology, St James\u2019 Institute of Oncology, Leeds"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology, St James\u2019 Institute of Oncology, Leeds","institution_ids":["https://openalex.org/I2801331674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088476247","display_name":"Marek Trn\u011bn\u00fd","orcid":"https://orcid.org/0000-0002-6952-6073","observed_orcids":["https://orcid.org/0000-0002-6952-6073"]},"institutions":[{"id":"https://openalex.org/I21250087","display_name":"Charles University","ror":"https://ror.org/024d6js02","country_code":"CZ","type":"education","lineage":["https://openalex.org/I21250087"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Marek Trneny","raw_affiliation_strings":["First Department of Medicine, Charles University General Hosp., Prague, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"First Department of Medicine, Charles University General Hosp., Prague, Czech Republic","institution_ids":["https://openalex.org/I21250087"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081516283","display_name":"Martin J.S. Dyer","orcid":"https://orcid.org/0000-0002-5033-2236","observed_orcids":["https://orcid.org/0000-0002-5033-2236"]},"institutions":[{"id":"https://openalex.org/I153648349","display_name":"University of Leicester","ror":"https://ror.org/04h699437","country_code":"GB","type":"education","lineage":["https://openalex.org/I153648349"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Martin J.S. Dyer","raw_affiliation_strings":["MRC Toxicology Unit, Leicester University, Leicester"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MRC Toxicology Unit, Leicester University, Leicester","institution_ids":["https://openalex.org/I153648349"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Swaminathan Padmanabhan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Swaminathan Padmanabhan","raw_affiliation_strings":["Cancer Therapy and Research center, UTHSCSA, San Antonio, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy and Research center, UTHSCSA, San Antonio, TX, USA","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102919781","display_name":"Tom\u00e1\u0161 Koz\u00e1k","orcid":"https://orcid.org/0009-0005-2446-7988","observed_orcids":["https://orcid.org/0009-0005-2446-7988"]},"institutions":[{"id":"https://openalex.org/I4210156160","display_name":"University Hospital Kralovske Vinohrady","ror":"https://ror.org/04sg4ka71","country_code":"CZ","type":"healthcare","lineage":["https://openalex.org/I4210156160"]}],"countries":["CZ"],"is_corresponding":false,"raw_author_name":"Tomas Kozak","raw_affiliation_strings":["Department Of Clinical Hematology,, University Hospital Kralovske Vinohrady, Prague, Czech Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department Of Clinical Hematology,, University Hospital Kralovske Vinohrady, Prague, Czech Republic","institution_ids":["https://openalex.org/I4210156160"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103114173","display_name":"Geoffrey W Chan","orcid":"https://orcid.org/0000-0001-6468-0103","observed_orcids":["https://orcid.org/0000-0001-6468-0103"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey Chan","raw_affiliation_strings":["GlaxoSmithKline, Collegeville, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Collegeville, PA, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012302432","display_name":"Randy L. Davis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randy L Davis","raw_affiliation_strings":["GlaxoSmithKline, Durham, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Durham, NC, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068017392","display_name":"Nedjad Losic","orcid":"https://orcid.org/0009-0003-9329-5425","observed_orcids":["https://orcid.org/0009-0003-9329-5425"]},"institutions":[{"id":"https://openalex.org/I4210163256","display_name":"Genmab (Denmark)","ror":"https://ror.org/057pe1087","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210163256"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Nedjad Losic","raw_affiliation_strings":["Genmab, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genmab, Copenhagen, Denmark","institution_ids":["https://openalex.org/I4210163256"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Charlotte A. Russell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163256","display_name":"Genmab (Denmark)","ror":"https://ror.org/057pe1087","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210163256"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Charlotte A. Russell","raw_affiliation_strings":["Genmab, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genmab, Copenhagen, Denmark","institution_ids":["https://openalex.org/I4210163256"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027293079","display_name":"Magdalena Piotrowska","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Magdalena Piotrowska","raw_affiliation_strings":["Department of Hematology, Klinika Hematologii CMUJ, Krakow, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Klinika Hematologii CMUJ, Krakow, Poland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047591504","display_name":"Joris Wilms","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163256","display_name":"Genmab (Denmark)","ror":"https://ror.org/057pe1087","country_code":"DK","type":"company","lineage":["https://openalex.org/I4210163256"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Joris Wilms","raw_affiliation_strings":["Genmab, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genmab, Copenhagen, Denmark","institution_ids":["https://openalex.org/I4210163256"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William G. Wierda","raw_affiliation_strings":["MD Anderson Cancer Centre, University of Texas, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Centre, University of Texas, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":7,"institutions_distinct_count":17,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":8.3148,"has_fulltext":false,"cited_by_count":44,"citation_normalized_percentile":{"value":0.9791061,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"112","issue":"11","first_page":"328","last_page":"328"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.9210000038146973},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.8999999761581421},{"id":"https://openalex.org/keywords/fludarabine-refractory-disease","display_name":"fludarabine-refractory disease","score":0.9300000071525574},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.7310000061988831},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.9430000185966492},{"id":"https://openalex.org/keywords/complement-dependent-cytotoxicity","display_name":"complement-dependent cytotoxicity","score":0.8119999766349792},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.382999986410141},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.4819999933242798},{"id":"https://openalex.org/keywords/interim-analysis","display_name":"interim analysis","score":0.4490000009536743},{"id":"https://openalex.org/keywords/time-to-next-therapy","display_name":"time to next therapy","score":0.5379999876022339}],"concepts":[{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.9418518543243408},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.8856924772262573},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.8244071006774902},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8137805461883545},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.6391674280166626},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6039491295814514},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.514069676399231},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.4657370150089264},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4587223529815674},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4414164423942566},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4042699337005615},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35992860794067383},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.2434295117855072},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.242110937833786},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.17655664682388306},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.12572962045669556},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.08642369508743286},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v112.11.328.328","doi":"https://doi.org/10.1182/blood.v112.11.328.328","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.328.328","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2124575836","https://openalex.org/W2597391618","https://openalex.org/W2500213562","https://openalex.org/W2094106544","https://openalex.org/W2142355921","https://openalex.org/W2249546605","https://openalex.org/W185506919","https://openalex.org/W2052868810","https://openalex.org/W2049353008","https://openalex.org/W3190055377"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"The":[2,28,151,207,274,376,508],"prognosis":[3,501],"for":[4,36,60,219,227,254,261,281,288,308,496],"patients":[5,38,111,191,240,335,426,439,468,497,513,565],"with":[6,19,42,90,112,119,146,305,323,373,469,480,493,498,514,528],"CLL":[7,123,249,471,516,630],"refractory":[8,16,515],"to":[9,17,33,247,271,457,628],"fludarabine":[10,18],"and":[11,78,114,149,178,202,223,258,285,340,355,393,405,437,533],"alemtuzumab":[12],"(double-refractory,":[13],"DR)":[14],"or":[15,121,381,472,587],"bulky":[20,473],"(>5cm)":[21],"lymphadenopathy":[22],"(bulky":[23],"fludarabine-refractory,":[24],"BFR)":[25],"is":[26,39,65],"poor.":[27],"overall":[29],"response":[30,159,301,609,613],"rate":[31],"(ORR)":[32],"salvage":[34],"therapy":[35,250],"such":[37],"approximately":[40],"20%":[41],"a":[43,66,72,98,171,236,295,365],"median":[44,275],"survival":[45,176,307],"of":[46,102,108,128,239,334,421,465,520,556,564],"9":[47,252],"mo":[48,253,260,280,287,632,641],"(Tam":[49],"et":[50],"al,":[51],"Leuk":[52],"Lym,":[53],"2007).":[54],"New":[55],"effective":[56],"treatments":[57,558],"are":[58],"needed":[59],"these":[61],"patients.":[62],"Ofatumumab":[63,320,476],"(HuMax-CD20)":[64],"human":[67],"monoclonal":[68,485],"antibody":[69,486],"that":[70],"targets":[71],"unique":[73],"small-loop":[74],"epitope":[75],"on":[76,97,327],"CD20":[77,92],"elicits":[79],"potent":[80],"in":[81,86,110,332,336,342,353,387,390,399,402,408,411,424,428,441,467,512,522,526,534],"vitro":[82],"complement-dependent":[83],"cytotoxicity,":[84],"even":[85],"malignant":[87],"B":[88],"cells":[89],"low":[91],"expression":[93],"levels.":[94],"We":[95],"report":[96],"planned":[99],"interim":[100,185],"analysis":[101,186,297],"an":[103,163,489],"international,":[104],"multicenter,":[105],"pivotal":[106],"study":[107],"ofatumumab":[109,129,466,521],"DR":[113,120,221,256,283,338,430,539],"BFR":[115,122,229,263,290,344,391,403,412,443,541],"CLL.":[116],"Methods:":[117],"Patients":[118,143],"received":[124,198,204],"8":[125,259,417],"weekly":[126],"infusions":[127,134,201],"followed":[130],"by":[131,162],"4":[132,382,561],"monthly":[133],"(Dose":[135],"1,":[136],"300":[137],"mg;":[138],"Doses":[139],"2\u201312,":[140],"2000":[141],"mg).":[142],"were":[144,180,347,384],"premedicated":[145],"paracetamol,":[147],"antihistamine":[148],"glucocorticoid.":[150],"primary":[152],"end":[153,165],"point":[154],"was":[155,215,251,268,277,302,321,363,477],"ORR":[156,208,598],"(1996":[157],"NCI-WG":[158],"criteria)":[160],"assessed":[161],"Independent":[164],"points":[166],"Review":[167],"Committee":[168],"(IRC)":[169],"over":[170],"24":[172],"wk":[173,299],"period.":[174],"Overall":[175,639],"(OS)":[177],"safety":[179],"also":[181],"evaluated.":[182],"Results:":[183],"This":[184,484],"included":[187],"all":[188,199],"138":[189],"treated":[190],"(DR,":[192],"n=59;":[193],"BFR,":[194],"n=79:":[195],"Table);":[196],"54%":[197],"12":[200],"90%":[203],"\u25a18":[205],"infusions.":[206,375],"(99%":[209,600],"CI)":[210,601,626],"based":[211,293],"upon":[212,294],"IRC":[213],"assessment":[214],"51%":[216],"(34,":[217,603],"68%)":[218],"the":[220,228,255,262,282,289,318,328,337,343,429,442,463],"group":[222,257,264,284,291,339,431,444],"44%":[224],"(30,":[225,606],"59%)":[226],"group;":[230],"1":[231,359,611],"patient":[232,453],"had":[233,241],"CR.":[234],"Additionally,":[235],"considerable":[237],"number":[238],"stable":[242],"disease":[243,524,617,621],"(Table).":[244],"Median":[245,624],"time":[246],"next":[248,629],"(Table);":[265,292],"clinical":[266,494],"progression":[267],"typically":[269],"due":[270],"worsening":[272],"lymphadenopathy.":[273],"OS":[276],"about":[278],"14":[279],"15":[286],"landmark":[296],"at":[298,317],"12,":[300],"significantly":[303],"correlated":[304],"longer":[306],"both":[309],"groups.":[310],"Updated":[311],"efficacy":[312],"results":[313,461],"will":[314],"be":[315],"presented":[316],"meeting.":[319],"associated":[322],"infusion-related":[324],"adverse":[325,367],"events":[326,370,395],"first":[329],"infusion":[330],"day":[331],"46%":[333],"38%":[341],"group,":[345],"which":[346],"grade":[348,351,360,379],"3":[349,361,380,438,622],"(no":[350],"4)":[352],"7%":[354],"3%,":[356],"respectively":[357],"(only":[358],"event":[362],"considered":[364],"serious":[366],"event).":[368],"These":[369,460],"generally":[371],"subsided":[372],"subsequent":[374],"most":[377],"common":[378],"toxicities":[383],"infections":[385],"(25%":[386],"DR;":[388,400,409],"27%":[389],"group)":[392,404],"hematologic":[394],"including":[396],"neutropenia":[397],"(12%":[398],"10%":[401],"anemia":[406],"(8%":[407],"4%":[410],"group).":[413],"Early":[414],"death":[415],"(within":[416],"wks":[418],"from":[419],"start":[420],"treatment)":[422],"occurred":[423],"2":[425],"(3%)":[427],"(sepsis,":[432],"n=1;":[433,446,448],"fungal":[434],"pneumonia,":[435],"n=1)":[436],"(4%)":[440],"(PD,":[445],"sepsis,":[447],"myocardial":[449],"infarction,":[450],"n=1).":[451],"No":[452],"tested":[454],"developed":[455],"antibodies":[456],"ofatumumab.":[458],"Conclusions:":[459],"demonstrate":[462],"effectiveness":[464],"double-refractory":[470],"fludarabine-refractory":[474],"disease.":[475],"well":[478],"tolerated":[479],"no":[481],"unexpected":[482],"toxicities.":[483],"potentially":[487],"represents":[488],"active":[490],"treatment":[491,506],"option":[492],"benefit":[495],"very":[499],"poor":[500],"who":[502],"have":[503],"exhausted":[504],"standard":[505],"options.":[507],"encouraging":[509],"single-agent":[510],"activity":[511],"warrants":[517],"further":[518],"investigation":[519],"earlier":[523],"settings,":[525],"combination":[527],"other":[529,535],"agents,":[530],"as":[531],"maintenance,":[532],"B-cell":[536],"malignancies.":[537],"Table":[538],"(n=59)":[540],"(n=79)":[542],"CI=confidence":[543],"interval;":[544],"NR=not":[545],"reached":[546],"Characteristic":[547],"Median(range)":[548],"Age,":[549],"yrs":[550],"64":[551],"(41\u201386)":[552],"62":[553],"(43\u201384)":[554],"No.":[555],"prior":[557],"5":[559],"(1\u201314)":[560],"(1\u201316)":[562],"%":[563],"Rai":[566],"Stage":[567,572],"III/IV":[568],"54":[569,597],"70":[570],"Binet":[571],"C":[573],"51":[574,602,614],"65":[575],"ECOG":[576],"performance":[577],"status":[578],"0":[579,610],"44":[580,605],"30":[581],"1\u20132":[582],"53":[583],"67":[584],"Lymph":[585],"node":[586],"CT":[588],"lesion":[589],">5cm":[590],"93":[591],"100":[592],"Prior":[593],"rituximab-containing":[594],"regimen":[595],"59":[596],"(%)":[599],"68)":[604],"59)":[607],"Complete":[608],"Partial":[612],"43":[615,619],"Stable":[616],"39":[618],"Progressive":[620],"10":[623],"(95%":[625],"Time":[627],"therapy,":[631],"9.0":[633],"(7.3,":[634],"10.7)":[635],"7.9":[636],"(7.1,":[637],"9.3)":[638],"survival,":[640],"13.7":[642],"(9.4,":[643],"NR)":[644],"15.4":[645],"(10.2,":[646],"20.2)":[647]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-10-25T00:00:00"}